Table 1 Main themes investigated in 2019
From: Harm reduction in Europe: a framework for civil society-led monitoring
Domain | Topic | Questions type |
|---|---|---|
OD prevention | ||
Policy level | Existence of OD prevention guidelines or policies (national and local) | Multiple choice (MC) |
Naloxone | Availability of naloxone (also in prison and to different groups of PWUD) and access barriers | MC + open ended (OE) |
Availability of take-home naloxone, access barriers, and divergences between official guidelines and practice | MC + OE | |
Cost and types of naloxone available | OE | |
Availability of naloxone training | MC + OE | |
Future plans to increase naloxone | OE | |
Drug consumption rooms | New initiatives and legal framework to allow for DCRs | MC + OE |
Prison settings | Availability of naloxone and pre-release naloxone in prison | MC + OE |
OD prevention upon release | MC | |
Other measures | Evaluation of first responders | OE |
Groups receiving OD prevention and education | MC + OE | |
OF and fentanyl | MC + OE | |
OD prevention for non-opioids | MC + OE | |
CSI | ||
Cooperation with policymakers | Level of cooperation between CSOs and policymakers (country level) | MC + OE |
Level of CSOs satisfaction with the cooperation | OE | |
Involvement in data collection | FPs contribution to data collection | MC + OE |
HCV | ||
National legislation | National legislation and guidelines for HCV treatment | MC |
Perceived impact of the guidelines on service accessibility for PWID | MC | |
Availability and restrictions of DAA’s for PWID | MC | |
Divergences between official guidelines on DAAs and practice | MC + OE | |
Continuum of care | Types of services providing testing and treatment for PWID | MC |
Service provider’s investment in prevention, testing or treatment | MC | |
PWUD networks participation on HCV advocacy | MC + OE | |
Main limitations to address HCV | OE | |
NDT | ||
Predominant ‘traditional’ drugs of use (country/region/city) | OE | |
Predominant new substances of use (country/region/city) | OE | |
Developments in the past 6 months (new substances or new groups of PWUD) | MC + OE | |
Description of new substances (name, period, appearance, price, (un) desired effects, etc. | MC + OE | |
Description of new groups of PWUD (substances used, forms of use, motives to use) | OE |